// App-Quantinova.ai

2909 : Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Researchers

Presenter

  • Justine Yu

Principal Investigators

  • Giovannino Silvestri

  • Lorenzo Stramucci

  • Denis-Claude Roy

  • Guido Marcucci

  • Bruno Calabretta

  • Maria R. Baer

  • Rossana Trotta

  • Danilo Perrotti

  • Masashi Sanada

  • Tomoyuki Yamaguchi

  • Yang Du

  • Jukka Westermarck

  • Michael A. Caligiuri

  • Ramiro Garzon

  • Dragana Milojkovic

  • Jane F. Apperley

Medical Centers

  • The James Comprehensive Cancer Center, Ohio State University, Columbus, OH

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA

  • Greenbaum Cancer Center, University of Maryland, Baltimore, MD

  • Haematology Department, Hammersmith Hospital (Imperial College Healthcare NHS Trust), London, United Kingdom

  • Department of Hematology and Cellular Therapy Laboratory, Hopital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada

  • Finnish Cancer Institute Turku Centre for Biotechnology, University of Turku, Turku, Finland

  • Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

  • Department of Defense, Uniformed Services University of the Health Sciences, Bethesda, MD

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • the Greenebaum Cancer Center, Dept. of Medicine, University of Maryland Baltimore, school of Medicine, Baltimore, MD

  • Division of Stem Cell Therapy, University of Tokyo, Tokyo, Japan

Locations

  • Finland

  • Canada

  • Japan

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • Lung disease, immunodeficiency, and chromosome breakage syndrome

Biomarkers

  • Protein Phosphatase 2 Phosphatase Activator

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved